Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Eyegate Pharma (EYEG)

Eyegate Pharma (EYEG)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 24,607
  • Shares Outstanding, K 12,619
  • Annual Sales, $ 10 K
  • Annual Income, $ -8,090 K
  • 60-Month Beta 0.81
  • Price/Sales 2,082.14
  • Price/Cash Flow N/A
  • Price/Book 1.34
Trade EYEG with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.24
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/08/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.34
  • Number of Estimates 2
  • High Estimate -0.29
  • Low Estimate -0.39
  • Prior Year -0.44
  • Growth Rate Est. (year over year) +22.73%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.7300 +12.72%
on 10/06/21
2.1900 -10.96%
on 10/21/21
+0.1400 (+7.73%)
since 10/05/21
3-Month
1.4400 +35.42%
on 08/18/21
2.3500 -17.02%
on 08/06/21
-0.4300 (-18.07%)
since 08/05/21
52-Week
1.4400 +35.42%
on 08/18/21
8.1800 -76.16%
on 12/21/20
-1.4400 (-42.48%)
since 11/05/20

Most Recent Stories

More News
EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company’s Sharpened Clinical Development Strategy

SALT LAKE CITY, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (“Kiora” or the “Company”) is the new name of EyeGate...

KPRX : 3.45 (-2.82%)
EYEG : 1.9500 (-1.52%)
EyeGate to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company developing and...

EYEG : 1.9500 (-1.52%)
EyeGate Pharma Completes Target Enrollment in Phase 2 Proof-of-Concept Study to Evaluate PP-001 for the Treatment of Ocular Surface Inflammation

-Proof-of-concept study conducted in Austria; Study designed to build upon positive Phase 1 safety data in healthy volunteers-

EYEG : 1.9500 (-1.52%)
EyeGate Pharma Reports Second Quarter 2021 Financial Results and Provides Business Update

WALTHAM, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products...

EYEG : 1.9500 (-1.52%)
EyeGate Announces Closing of $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

WALTHAM, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for...

EYEG : 1.9500 (-1.52%)
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

WALTHAM, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for...

EYEG : 1.9500 (-1.52%)
EyeGate Pharmaceuticals Announces Appointment of Brian M. Strem, Ph.D., as President and Chief Executive Officer

-EyeGate signs non-binding letter of intent to acquire Bayon Therapeutics, a private ophthalmic pharmaceutical company developing a novel, vision restoring small molecule platform-

EYEG : 1.9500 (-1.52%)
EyeGate Pharma Announces First Patient Dosed for PP-001 in a Phase 2 Proof-of-Concept Ocular Surface Inflammation Study

- Proof-of-concept study conducted in Austria- -Topline data expected in Q4 2021-

EYEG : 1.9500 (-1.52%)
EyeGate Pharma Reports First Quarter 2021 Financial Results and Provides Business Update

- PP-001: proof-of-concept study in Austria for dry eye patients expected to initiate in Q3:21; U.S. IND submission planned in Q4:21-

EYEG : 1.9500 (-1.52%)
EyeGate Pharma Announces the Appointment of Kenneth Gayron and Aron Shapiro to its Board of Directors

WALTHAM, Mass., April 01, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing products for treating inflammatory...

EYEG : 1.9500 (-1.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

EyeGate Pharmaceuticals, Inc. is a pharmaceutical company which is engaged in developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The company's technology consists of EyeGate(R) II Delivery System. Its product pipeline includes EGP-437 which is in different...

See More

Key Turning Points

3rd Resistance Point 2.0733
2nd Resistance Point 2.0367
1st Resistance Point 1.9933
Last Price 1.9500
1st Support Level 1.9133
2nd Support Level 1.8767
3rd Support Level 1.8333

See More

52-Week High 8.1800
Fibonacci 61.8% 5.6053
Fibonacci 50% 4.8100
Fibonacci 38.2% 4.0147
Last Price 1.9500
52-Week Low 1.4400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar